Veterinary medicines European public assessment report (EPAR): Eurican L4, inactivated immunological veterinary medicinal product containing Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 16070, L. interrogans, serogroup icterohaemor

Submitted by Anonymous (not verified) on 11 March 2024 - 14:40

Veterinary medicines European public assessment report (EPAR): Eurican L4, inactivated immunological veterinary medicinal product containing Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 16070, L. interrogans, serogroup icterohaemorrhagiae, serovar icterohaemorrhagiae, strain 16069, L. interrogans, serogroup Grippotyphosa, serovar Grippotyphosa, strain Grippo Mal 1540, L. interrogans, serogroup Australis, serovar Bratislava, strain, Status: Authorised

Committee for Medicinal Products for Human Use (CHMP): 22-25 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 22 January 2024 to 25 January 2024

Submitted by Anonymous (not verified) on 11 March 2024 - 10:28

Committee for Medicinal Products for Human Use (CHMP): 22-25 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 22 January 2024 to 25 January 2024

Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0421/2019

Submitted by Anonymous (not verified) on 8 March 2024 - 15:02

Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0421/2019

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness